天眼查App显示，涉事企业大参林医药集团股份有限公司（简称：大参林，603233.SH）成立于 1999年2月，法定代表人为柯国强，注册资本约11.4亿人民币，经营范围包括药品批发、药品零售、药 品进出口等，由柯云峰、柯金龙、柯康保等共同持股。法律诉讼信息显示，该公司曾多次因产品责任纠 纷、买卖合同纠纷等被起诉。 (责任编辑：徐自立) 中国经济网北京2月27日讯（记者 马先震） 紫牛新闻春节期间报道《女子称用了药店推荐药突然 耳聋》显示，张女士前段时间左耳不舒服，到大参林大药房拿药时，店员称她是中耳炎，推荐了氧氟沙 星滴耳液、过氧化氢消毒液，张女士滴到耳朵里后竟然聋了！经过治疗后，张女士听力有所好转，但 4000多元治疗费药店却不管不问。药房店员称有执业药师证，但没有行医资质，当时是线上平台医生 诊断，没有查看耳内具体情况。药店负责人表示张女士的诉求需要医院提供确由药物导致耳聋的证明， 如果没有，最多赔付200元，并让员工进行赔礼道歉。 中国经济网记者致电大参林，对方表示需要需要向上级反馈，截至发稿时记者暂未收到回复。 ...

Summary of Conference Call on Healthcare Services and Pharmacy Sector Industry Overview - The focus is on the healthcare services and pharmacy sectors within the pharmaceutical industry, particularly consumer-oriented segments, which are currently viewed positively due to historical low valuations after a prolonged adjustment period [1][2]. Key Points and Arguments Healthcare Services - The healthcare services sector has experienced significant declines, with current valuations at historical lows, indicating a potential for recovery by 2026 [1]. - Specific companies highlighted for their optimistic 2026 guidance include Tongce Medical, Gushengtang, and Aier Eye Hospital, all expected to show double-digit growth [1][2]. - The recovery in the sector is anticipated to be driven by improvements in supply structure and consumer environment, leading to a business rebound [2]. - Aier Eye Hospital is introducing new consumer-oriented surgical procedures, which may increase average transaction values despite stable surgical volumes [2]. Market Trends - Data from October 2025 shows positive growth in outpatient services in cities like Chongqing and Tianjin, with increases of 5-6% and 13-14% respectively [3]. - The overall trend indicates a recovery in both service volume and pricing, particularly in consumer-oriented medical fields like ophthalmology [3][4]. AI Integration - AI is expected to empower healthcare service companies, with applications like Ant Group's AI health app showing significant user growth, indicating a new growth driver for leading healthcare service firms [4][5]. Pharmacy Sector - The pharmacy sector is experiencing notable improvements in performance since Q3 2025, with leading companies showing consistent same-store sales growth [6]. - The sector is supported by government policies aimed at increasing industry concentration and chain store rates, which are expected to drive medium-term performance [6][7]. - Companies like Yifeng Pharmacy and Dazhong Pharmacy are highlighted for their strong cash flow and dividend yields, with Dazhong reporting a 60% dividend payout ratio [6][7]. Online vs. Offline Dynamics - The online pharmacy market is growing rapidly, but it serves a different demographic compared to traditional pharmacies, which cater more to older consumers [7][8]. - The online pharmacy market is projected to grow significantly, driven by products like GLP-1, but the overall growth rate may stabilize as both online and offline markets adjust [9][10]. Regulatory Environment - Recent government policies emphasize enhancing pharmacy service capabilities and supporting prescription outsourcing, which could lead to increased revenue opportunities for pharmacies [13][14]. - The focus on compliance and competition is expected to benefit larger pharmacy chains with established networks and resources for mergers and acquisitions [17]. Home Medical Devices - The home medical device sector is poised for growth due to an aging population and increasing health awareness, with significant potential in health monitoring devices like blood pressure monitors and glucose meters [18][19]. - Companies such as Yuyue Medical and Sanofi are recommended for their strong growth prospects in this segment [21]. Conclusion - The healthcare services, pharmacy, and home medical device sectors are expected to experience a bottom reversal, driven by improving fundamentals and supportive government policies. Key players in these sectors are well-positioned to capitalize on these trends, making them attractive investment opportunities moving forward [1][21].

Investment Rating - The industry investment rating is "Positive" (maintained) [5][41]. Core Insights - The medical services and pharmacy sectors have undergone significant adjustments since 2021, with valuations and performance returning to historically low levels. For instance, leading companies like Aier Eye Hospital, Tongce Medical, and Yifeng Pharmacy have seen their total market values decline by 73.5%, 81.9%, and 45.9% respectively since the Spring Festival of 2021 [1][16]. - The consumer medical industry is experiencing an improvement in competition and safety margins, aided by the implementation of relevant policies and a potential recovery in consumer willingness to spend [2]. - The offline pharmacy sector is benefiting from policy incentives and an improved competitive landscape, with significant support for prescription outflow and industry restructuring [3][32]. Summary by Sections 1. Valuation Bottoming and Low Holdings - The medical services and pharmacy sectors have faced prolonged adjustments, leading to valuations at historically low levels. The public fund holdings in these sectors have also decreased [10][11]. - The leading companies in the industry have seen substantial market value adjustments, indicating a low public fund holding ratio [16]. 2. Accumulating Reversal Momentum - The medical services and pharmacy sectors are expected to experience a dual recovery in performance and valuation, driven by improved competition and policy clarity [21]. - The medical services sector is witnessing a gradual recovery in income growth, particularly in the ophthalmology sector, which has seen a slowdown in revenue growth after a rapid recovery period [22]. - The pharmacy sector is experiencing a shift towards health service platforms, supported by policy changes that encourage pharmacies to expand their service offerings [33]. 3. Investment Views - Focus on leading companies in the medical services sector that have strong chain expansion capabilities and supply chain advantages, such as Aier Eye Hospital and Tongce Medical, which are expected to benefit from consumer upgrades and market demand [4][37]. - In the pharmacy sector, attention should be given to leading chains with strong supply chain advantages and management capabilities, such as Yifeng Pharmacy and Dazhenglin, which are well-positioned to capture market share and benefit from policy changes [4][37].

Core Viewpoint - The report highlights the financing, investment, logistics, and merger activities of China's chain pharmacy industry, emphasizing the importance of logistics center construction and the trend of expanding business scale and diversification among leading companies [1][8]. Financing Situation - The primary financing methods for listed companies in the chain pharmacy industry include private placements and convertible bonds, mainly aimed at constructing logistics centers, opening new pharmacies, and supplementing working capital [1]. - Key financing events since 2022 include: - Yifeng Pharmacy raised 2.547 billion yuan for logistics and digital platform upgrades [1]. - Yixin Tang raised up to 1.5 billion yuan for new pharmacies and logistics projects [1]. - Daclin raised 3.025 billion yuan for new chain pharmacies [1]. - Shuyupingmin raised up to 800 million yuan for modern logistics projects [1]. - Jianzhijia raised 410 million yuan for logistics center projects [1]. Investment Activities - From 2020 to 2025, major companies like Daclin, Yifeng Pharmacy, and Laobaixing have been actively investing, with Daclin leading with 36 investment events, followed by Yifeng Pharmacy with 14 and Laobaixing with 13 [5][6]. - The investment purposes include expanding business scale and diversifying operations, with companies investing in subsidiaries across different regions to enhance their market presence [8][10]. Merger and Acquisition Trends - Recent mergers and acquisitions in the chain pharmacy industry are primarily aimed at expanding the scale of midstream enterprises, often involving the acquisition of other pharmacy brands to increase store numbers and improve regional business layouts [11]. - Notable merger events include: - Huaren Health's acquisition of three pharmacy chains in Fujian and Zhejiang to expand its market presence [11]. - Yixin Tang's acquisition of multiple pharmacies in Sichuan to enhance competitiveness [11]. - Laobaixing's acquisition of a pharmacy chain in Anhui to strengthen market position [11]. Logistics Center Development - The construction of logistics centers is identified as a major purpose for financing, with companies focusing on enhancing their supply chain efficiency and operational capabilities [1][8].

Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

A股这7大板块，勾勒出中 国经济全貌 出品 | 妙投APP 作者 | 妙投团队 编辑 | 丁萍 头图 | AI制图 幸福的人大致相同，不幸的人各有各的不幸。 银河证券研报显示，截至1月31日，2956家A股上市公司已披露2025年年报业绩预告，披露率为54%。其中 电机、地面兵装、个护用品、风电设备预喜率 （包括扭亏、续盈、略增、预增等情形） 超过70%，汽车行 业超过50%，受益于AI算力需求的电子和通信行业，预喜率分别达到45%和37%。这些大体上属于科技、高 端制造、新消费等领域。 而传统行业，大多较为一般。 煤炭、房地产、轻工制造、建筑装饰、食品饮料、社会服务、石油石化等行业预喜率较低，均低于25%； 焦炭、体育、林业、农业综合、厨卫电器、油气开采、白酒行业预喜率更是均为0%；传统行业中预喜率较 高的，主要是非银金融、有色金属、钢铁、公用事业等少数行业。 展望2026年，有些业绩不错的行业，有望继续保持成长。而有些2025年经营惨淡的行业，也有边际复苏的 机会，或者有复苏的预期。 这句话放到宏观经济各个层面中来看，也是如此。有的行业经历着良好的增长，有的行业在期待着复苏的 曙光。 2025年到现在，无 ...

2016-2025年医药制造业企业数统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：国药现代（600420），昆药集团（600422），片仔癀（600436），千金药业（600479），津 药药业（600488），国药股份（600511），联环药业（600513），合富中国（603122），康惠制药 （603139），莎普爱思（603168），奥翔药业（603229），大参林（603233） 相关报告：智研咨询发布的《2026-2032年中国医药制造外包（CMO/CDMO）行业市场发展态势及未来 趋势研判报告》 2025年1-12月，医药制造业企业数（以下数据涉及的企业，均为规模以上工业企业，从2011年起，规模 以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为9875个， 和上年同期相比，增加了82个，同比增长 ...

公司情报专家《财经涂鸦》获悉，2月3日，弗若斯特沙利文（Frost & Sullivan）发布《中国智慧零售市场追踪报告（2025H1）》。 数据显示，2025年上半年，中国智慧零售整体市场规模达107亿元人民币，腾讯以25.3%的整体市场份额位列第一。 除整体市场份额领跑外，腾讯还在食品饮料及酒水、零售商超、运动鞋服等多个核心行业，以及解决方案市场子项中斩获份额第一。其中，在零售商超赛 道占比高达40.8%，居绝对领导地位。 该报告首次聚焦实体零售企业在数字化转型和全域经营中所创造的综合服务价值，统计范围覆盖云基础设施与平台服务(IaaS+PaaS)、SaaS及解决方案。 沙利文指出，智慧零售是面向零售企业的一套端到端经营解决方案，通过统一的消费者运营与门店经营体系，协同"人、货、场"的关键业务环节，驱动可 衡量的增长与体验提升。2025年以来，受AI技术应用爆发驱动，智慧零售增长动能明显增强。 报告预测，到2030年，中国智慧零售市场规模将有望达到约645亿元，年复合增长率达到22%。 自2018年启动产业互联网转型，腾讯面向零售行业成立专属团队，如今行业覆盖商超、餐饮、食品饮料及酒水、快消日化、鞋服运动 ...

转自：新华财经 2月3日，国际权威咨询机构弗若斯特沙利文（Frost & Sullivan）发布《中国智慧零售市场追踪报告 （2025H1）》。数据显示，2025年上半年，中国智慧零售整体市场规模达107亿元人民币，腾讯以 25.3%的整体市场份额位列第一。 除整体市场份额领跑外，腾讯还在食品饮料及酒水、零售商超、运动鞋服等多个核心行业，以及解决方 案市场子项中斩获份额第一。其中，在零售商超赛道占比高达40.8%，居绝对领导地位。 依托腾讯大数据选址能力，瑞幸获得更加精准的点位推荐，快速筛选合适的空白市场，加速下沉市场的 开店扩张。腾讯云的弹性伸缩容能力，以及架构师的实时保驾护航，帮助瑞幸扛住一次次流量洪峰。 周大福基于腾讯企点营销云，打造全渠道会员平台，实现中港澳三地会员身份识别与权益互通，提升超 5000万会员的全渠道购物体验；助力好想来精细化运营1.5亿会员、驱动万店协同，实现分钟级"千人千 面"精准营销，促进会员活跃度与客单价双提升。 扎根产业场景，落地"好用的AI" 随着国家"人工智能+"行动的深入推进，AI的应用正从零散的单点尝试，走向系统化的全场景全链路渗 透。报告指出，AI已成为智慧零售降本增 ...

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...